Abstract Estrogen (E 2 )-induced transcription requires coordinated recruitment of estrogen receptor a (ER) and multiple factors at the promoter of activated genes. However, the precise mechanism by which this complex stimulates the RNA polymerase II activity required to execute transcription is largely unresolved. We investigated the role of bromodomain (BRD) containing bromodomain and extra-terminal (BET) proteins, in E 2 -induced growth and gene activation. JQ1, a specific BET protein inhibitor, was used to block BET protein function in two different ERpositive breast cancer cell lines (MCF7 and T47D). Realtime PCR and ChIP assays were used to measure RNA expression and to detect recruitment of various factors on the genes, respectively. Protein levels were measured by Western blotting. JQ1 suppressed E 2 -induced growth and transcription in both MCF7 and T47D cells. The combination of E 2 and JQ1 down-regulated the levels of ER protein in MCF7 cells but the loss of ER was not responsible for JQ1-mediated inhibition of E 2 signaling. JQ1 did not disrupt E 2 -induced recruitment of ER and co-activator (SRC3) at the E 2 -responsive DNA elements. The E 2 -induced increase in histone acetylation was also not altered by JQ1. However, JQ1 blocked the E 2 -induced transition of RNA polymerase II from initiation to elongation by stalling it at the promoter region of the responsive genes upstream of the transcription start site. This study establishes BET proteins as the key mediators of E 2 -induced transcriptional activation. This adds another layer of complexity to the regulation of estrogen-induced gene activation that can potentially be targeted for therapeutic intervention.
Introduction
Transcriptional activation of genes by estrogen (E 2 ; 17b-estradiol) is a highly regulated process that requires the coordinated interaction of estrogen receptor a (ER) with estrogen responsive elements (EREs), followed by the binding of co-regulators and other chromatin-modifying factors [1, 2] . Co-regulators, which can be co-activators or co-repressors, can recruit other co-factors with diverse enzymatic activities required for modulating the transcriptional process [3] . E 2 -liganded ER and the p160 family of co-activators (SRC1, SRC2, and SRC3) form a dynamic transcription activation complex [1, 4] that interacts with CBP and p300 co-activators [5] possessing intrinsic histone acetyl-transferase (HAT) activity [6] [7] [8] . Addition of acetyl groups specifically occurs at the lysine residues of the N-terminal histone proteins by HAT activity, resulting in enhanced accessibility of the chromatin to the transcriptional machinery [9] . These chromatin alterations eventually lead to the synthesis of the RNA of E 2 -responsive genes by RNA polymerase II (RNAP)
Electronic supplementary material The online version of this article (doi:10.1007/s10549-015-3319-1) contains supplementary material, which is available to authorized users. [4, 10] . However, the components and the events responsible for ''reading'' the hyper-acetylated histone chromatin, which are necessary to integrate RNAP activation in the context of E 2 -regulated genes, are poorly understood.
Studies have established that dual bromodomain containing bromodomain and extra-terminal (BET) proteins, which include BRD2, BRD3, and BRD4, plays important roles in stimulation of transcription by RNAP [11] [12] [13] . The bromodomains of the BET proteins bind to acetylated lysines of the histones, whereas the extra-terminal (ET) domain of the protein can interact independently with multiple other proteins [14] . BRD4 interacts with the positive transcription elongation factor b (PTEFb) [11] , which is responsible for the transcriptional elongation by RNAP [14] . BRD2 and BRD3 also bind to hyper-acetylated histone 3 (H3) and histone 4 (H4) and permit transcriptional elongation by RNAP [13] . Interest in the BET proteins has increased recently due to the discovery of the potential therapeutic selective inhibitor of BET bromodomains, JQ1, which can block the interface of the bromodomain responsible for recognizing the acetylated lysines in histones [16] . JQ1 has been used extensively as a chemical tool to delineate the effects of BET proteins in various disease-specific studies [16] [17] [18] [19] [20] [21] [22] .
However, the roles of BET proteins in E 2 -induced transcription in the ER-positive breast cancers have not been examined before. We studied the effect of BET protein inhibition using JQ1 on the growth and the transcriptional regulation of estrogen (E 2 )-stimulated genes in two distinct ER-positive breast cancer cell lines (MCF7 and T47D). These cells regulate the ER differently [23] . By studying three established and well characterized E 2 -regulated genes namely, pS2 (TFF1) [1, 2] , GREB1 [24] , and XBP1 [25, 26] , this study demonstrates the key role of the BET proteins in E 2 -induced transcription by ER.
Materials and methods

Cell culture and reagents
Cell culture media were purchased from Invitrogen Inc. (Grand Island, NY) and fetal calf serum (FCS) was obtained from HyClone Laboratories (Logan, UT). The ERa? breast cancer cells MCF-7:WS8 (mentioned as MCF7 hereafter) were derived from MCF7 cells [27] obtained from Dr. Dean Edwards, San Antonio, Texas and T47D A:18 cells (mentioned as T47D hereafter) were derived from T47D cells as reported previously [28] . The cells were maintained in phenol red-containing RPMI media supplemented with 10 % FCS. Three to four days prior to treatment, the cells were cultivated in phenol red-free media containing 10 % charcoal dextran-treated FCS. BET protein inhibitor, JQ1 (cat # 4499) was purchased from Tocris Bioscience, (Bristol, UK) and the inactive JQ1 stereoisomer (cat # A8181) was purchased from Apex Bio Technologies (Boston, MA). All the experiments were performed at least three times, in triplicate to confirm the results.
Cell growth assay
Cell growth assays were performed by measuring the total DNA per well in 24-well plates. Eight thousand cells were plated per well and treatment with indicated concentrations of compounds was started after 24 h, in triplicates. Media with specific treatments were changed every 48 h. Cells were harvested after 6 days of treatment in hypotonic buffer solution followed by sonication. Total DNA was measured using a fluorescent dye (Hoechst 33,258) in the DNA quantitation kit (Cat # 170-2480; Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions.
RNA isolation and real-time PCR
TRIzol reagent (Invitrogen, Carlsbad, CA) and RNAeasy kit (Qiagen, Valencia, CA, USA) were used to isolate total RNA according to the manufacturer's instructions. Realtime PCR was performed as previously described [29] . Briefly, cDNA was generated from 1 ug of total RNA in a total volume of 20 ll using High-Capacity cDNA Reverse Transcription kits (Applied Biosystems, Foster City, CA). Subsequently, the cDNA was diluted to 500 ll and RT-PCR was performed using ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). Each well contained 10 ll SYBR green PCR master mix (Applied Biosystems, Foster City, CA), 125 nM each of forward and reverse primers and 5 ll of diluted cDNA in 20 ll final volume. The change in expression of transcripts was determined as described previously and used the ribosomal protein 36B4 mRNA as the internal control [29] . Details of the primers used for TFF1, GREB1, XBP1, ER alpha, and 36B4 genes can be found in supplementary Table 1 .
Western blotting RIPA buffer containing protease inhibitors (Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitors I and II (EMD Chemicals Inc. San Diego, CA) was used to extract whole-cell protein lysates. 15-20 lg of total protein was run on the gels and transferred onto nitrocellulose membranes. Membranes were subsequently blocked with 5 % non-fat dry milk in tris-buffered saline and probed with primary and secondary antibodies. Specific bands were visualized using West Pico Chemiluminescence (Thermo Fisher, Rockford, IL, USA). The antibodies used were ER alpha (#sc-544; Santa Cruz Biotechnology, Dallas, TX) and beta actin (#A5441; Sigma, St. Louis, MO).
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as described previously [29] . Briefly, cells were treated with the indicated treatments for 45 min and cross-linked using 1.25 % paraformaldehyde for 15 min and subsequently cross-linking was stopped with 2 M glycine. Nuclei were isolated from cells that were re-suspended in SDS lysis buffer followed by sonication and centrifugation at 14,0009g for 20 min at 4°C. The supernatants were diluted 1:10 with ChIP dilution buffer. Pre-clearing of the samples was performed by normal rabbit IgG and protein A magnetic beads (Upstate cell signaling solutions, Temecula, CA) followed by over-night incubation using specific antibodies against ER alpha (1:1 ratio of sc-7207 and sc-543; Santa Cruz Biotechnology, Dallas, TX), SRC3 (sc-13066; Santa Cruz Biotechnology, Dallas, TX), acetylated histone 4 (06-866; Upstate cell signaling solutions, Temecula, CA), and RNA polymerase II (sc-56767; Santa Cruz Biotechnology, Dallas, TX). The immuno-complexes were pulled down using protein A magnetic beads (Upstate cell signaling solutions, Temecula, CA). Beads bound to immuno-complexes were thereafter washed and precipitates were extracted twice using freshly made 1 % SDS and 0.1 M NaHCO 3 followed by de-crosslinking. DNA fragments were purified using the Qiaquick PCR purification kit (Qiagen, Valencia, CA). RT-PCR was performed using 2 ll isolated DNA, using locispecific primers. Details of the primer sequences for the promoters and gene coding region can be found in the supplementary Table 2 . The data are represented as fold enrichment over normal IgG pull down for each treatment sample after calculating the percent input. The ''traveling ratio'' of the RNAP, which is a measurement of its elongation function [30] , was calculated as the ratio of fold enrichment of RNAP at the promoter to the coding region for each gene.
Statistics
Statistical significance of our data was calculated using the paired Student's ''t'' test wherever relevant. A p value of \0.05 was considered as statistically significant.
Results
JQ1 blocks E 2 -induced cell proliferation and ERmediated gene activation in MCF7 and T47D breast cancer cells
Most estrogen receptor-positive breast cancers depend upon estrogen for cell proliferation and growth. We examined the dose-dependent effect of the BET protein inhibitor, JQ1, on E2-induced growth of MCF7 and T47D breast cancer cells. JQ1 inhibited E 2 -induced growth of both the breast cancer cell lines in a concentration-dependent manner (Fig. 1a, b) . In both cell lines, 500 nM JQ1 was sufficient to block the E 2 -induced growth completely over a 6-day period. This growth inhibition was due to a reduction in proportion of the cells in ''S'' phase cells by JQ1 as evidenced by the cell cycle analysis (supplementary Fig. 1a, b) . Basal growth of the cells in the absence of E 2 was also moderately inhibited over this time period. Next, we examined the inhibitory effect of JQ1 on ER-mediated transcriptional activation of representative E 2 -responsive genes, TFF1, GREB1, and XBP1. Expression of all these genes was up-regulated by 1 nM E 2 after 6 h of treatment in both MCF7 and T47D cells, an effect that was almost completely inhibited by JQ1 (Fig. 1c-h) . A well-defined dose-dependent inhibitory effect of JQ1 was not evident as even the lowest concentration of JQ1 (125 nM) blocked E 2 -induced gene activation and the higher concentrations of JQ1 did not enhance this effect significantly.
Inhibition of E 2 -induced gene activation by JQ1 is enantiomer specific and is rapidly reversible
To investigate specificity of JQ1-mediated inhibition, we used the inactive enantiomer of JQ1 ((-)-JQ1; Fig. 2a ) that is unable to bind the acetyl-lysine binding pocket of the bromodomain [16] . (-)-JQ1 (250 nM) failed to inhibit the E 2 -induced gene activation of TFF1, GREB1, and XBP1 in both MCF7 and T47D cells (Fig. 2c, through 2h ), when compared with the 250 nM JQ1 treatment in combination with E 2 . E 2 -induced growth over a period of 6 days, of both MCF7 and T47D cells also was not inhibited by (-)-JQ1 ( Fig. 2b ) unlike JQ1. To further examine if there was an extended inhibitory effect of JQ1 on E 2 -regulated genes, even after the withdrawal of JQ1, we treated the MCF7 cells with E 2 (1 nM) ? JQ1 (250 nM) for 2 h, and then removed JQ1 from the media and maintained the cells under E 2 (1 nM) treatment for 30, 60, and 120 min. As expected, 2 h of JQ1 treatment (250 nM) in combination with E 2 almost completely blocked the E 2 activation of the TFF1, GREB1, and XBP1 genes ( Fig. 3a-c) . However, withdrawal of JQ1 from the treatment rapidly (within 120 min) restored the hormone-mediated activation of all the genes to a level comparable to E 2 treatment alone after 2 h (Fig. 3a-c) . Interestingly, the kinetics of the activation of these genes after JQ1 withdrawal ( Fig. 3a-c) and with E 2 treatment alone ( Fig. 4e-g ) were the same. Thus, JQ1-mediated inhibition is not only reversible but also its constant presence is necessary for its effectiveness.
JQ1 and E 2 combination drastically reduces ER levels in MCF7 cells but is not responsible for the inhibitory effect of JQ1
To examine the effect of JQ1 ? E 2 combination treatment on the expression of ER, we determined the levels of ER protein and mRNA in E 2 ? JQ1-treated MCF7 and T47D cells. Different regulations of ER protein expression were observed for the two cell lines. T47D cells did not show any remarkable change in ER protein levels after E 2 ? JQ1 treatment for 6 h (Fig. 4b) . In contrast, MCF7 cells exhibited drastic reduction of ER protein after 6 h of E 2 ? JQ1 treatment (Fig. 4a) , whereas the reduction was less evident in cells treated with E 2 or JQ1 alone. Opposing , and e, respectively) were assessed in MCF7 cells using real-time PCR after 6 h of treatment with Vehicle (Veh) or E 2 or indicated concentration of JQ1 in combination with E2. Levels of TFF1, GREB1, and XBP1 mRNA (f, g, and h, respectively) were assessed in T47D cells using real-time PCR after 6 h of treatment with Vehicle (Veh), E 2 , JQ1 or indicated concentration of JQ1 in combination with E 2 . (*p \ 0.05 vs. E 2 treatment alone) regulation of ER mRNA in MCF7 and T47D cells was observed; JQ1 and E 2 combination treatment suppressed the levels of ER mRNA in MCF7 (Fig. 4c) but not in T47D cells (Fig. 4d) . However, treatment with JQ1 alone reduced the ER mRNA levels by 40-50 % in both the cell lines (Fig. 4c, d ). Conversely, E 2 alone increased ER mRNA expression in T47D cells but no change was observed in MCF7 cells. Since ER protein levels were significantly reduced in MCF7 cells treated with JQ1 ? E 2 , we investigated if these changes in ER were responsible for the impairment of the E 2 gene regulation. We first focused on the early time points after hormone treatment and found that E 2 up-regulated TFF1 and XBP1 within 60 min and GREB1 within 120 min of treatment ( Fig. 4e-g ). JQ1 completely blocked this up-regulation at each time point, whereas expression of ER protein did not alter significantly during this time period (Fig. 4h ) except for the 120 min treatment with JQ1 ? E 2 . To determine further if exogenous ER expression can reverse the JQ1-mediated inhibition of E2-regulated genes, we over-expressed ER in MCF7 cells using a tet-off adenovirus system [31] and treated the cells with vehicle, E2, JQ1, and E2 ? JQ1 for 18 h. Exogenous ER expression (supplementary Fig. 2a ) was unable to rescue the JQ1-mediated inhibition of E 2 -regulated genes (supplementary Fig. 2b, c, d ), further confirming that the inhibitory effect of JQ1 was not dependent on the reduced ER expression in MCF7 cells.
JQ1 treatment does not disrupt E 2 -induced recruitment of ER, SRC3, or histone acetylation status at the promoters of genes To understand the mechanism by which JQ1 inhibited the E 2 -induced transcription of responsive genes, we examined if JQ1 disrupted the recruitment of ER and/or the coactivator SRC3 at the promoters of the responsive genes after E 2 treatment. Recruitment of these factors at the promoter regions of TFF1, GREB1, or XBP1 genes harboring EREs (Fig. 5a , e, i) was investigated using ChIP assays in MCF7 cells. These ERE sites have been well characterized and recruitment of ER and other factors at these sites have been associated with E 2 -induced transcription of these genes [1, 24-26, 32, 33] . Recruitment of ER and SCR3 at these sites was evaluated after 45 min of treatment with vehicle, E 2 , JQ1, and E 2 ? JQ1. As expected, E 2 treatment induced recruitment of both ER and SRC3 at the promoter EREs of each of the TFF1, GREB1, and XBP1 genes (Fig. 5b, c , f, g, j, k). This recruitment was associated with E 2 -induced hyper-acetylation of histone H4 (Fig. 5d, h, l) . Treatment with JQ1 alone had no effect on these parameters. Interestingly, JQ1 ? E 2 also did not affect the E 2 -induced recruitment of ER and SRC3 at the TFF1 and GREB1 promoters. In the case of XBP1, a slight suppression in recruitment of ER and SRC3 was observed in the presence of JQ1. Modest reduction in E 2 -induced hyper-acetylation of H4 was observed by JQ1 in the TFF1 and GREB1 genes but not with XBP1 (Fig. 5d , h, l). JQ1 blocks E 2 -induced RNA polymerase II (RNAP) advancement from the promoters to the coding region of the gene Since E 2 -induced recruitment of RNAP and its elongation activity at the promoters of the responsive genes is necessary to stimulate the transcription process, we measured enrichment of the RNAP by ChIP assay followed by locispecific qRT-PCR. To evaluate its density at the proximal promoter, we designed primers for the loci that were upstream of the transcription start site. For TFF1 and GREB1, these were the same regions that contained the ERE. For XBP1, we used primers for 300 bp upstream region, which recruits higher level of RNAP than the enhancer region (-13 kb) containing the ERE [26] . To assess the elongation activity of the RNAP enzyme, we evaluated its enrichment (density) at the coding region of the gene body of all the three genes. The density of RNAP on the gene body positively correlates with its transcriptional elongation activity in MCF7 cells [34] . Therefore, separate primers were used to assess the RNAP recruitment in the coding region of each gene as outlined in the Fig. 6a , e, and i. The results revealed that JQ1 marginally (19-35 %) suppressed E 2 -induced RNAP recruitment at the proximal promoter of all the genes tested (Fig. 6b, f, j) . In contrast, RNAP recruitment was notably lower (*80 %) in the coding region of the gene body for TFF1 and GREB1 in presence of JQ1 and E 2 (Fig. 6c, g ). For XBP1, we observed a 45 % reduction in RNAP recruitment in the gene body (Fig. 6k) compared with E 2 only. A measure of transitional activity from initiation to elongation of RNAP can be represented by the ''traveling ratio'', which depicts the ratio of RNAP association with the promoter to the coding region [30] . Evaluation of the traveling ratio showed that E 2 treatment was associated with a substantial reduction in the traveling ratio for TFF1, GREB1, and XBP1 (Fig. 6d, h, l) , indicating proficient transcription elongation activity. The reduction in traveling ratio by E 2 was fully reversed by JQ1 treatment for TFF1 and GREB1, but only slightly for XBP1 gene (Fig. 6d, h, l) . Interestingly, XBP1 also showed high recruitment of RNAP at the promoter and in the coding region even in the absence of E 2 , which was not reversed by JQ1 alone (Fig. 6j, k) . In fact at the promoter region of XBP1 gene, JQ1 alone enhanced the recruitment of the RNAP as compared with vehicle (Fig. 6j) .
Discussion
Histone acetylation at the promoters of E 2 -induced genes is one of the key chromatin modifications required for the activation of transcription [8, 10] . Based on our data, we postulate (Fig. 7) that the BET proteins, which can recognize the acetylated histones in the chromatin [35, 36] and allow transcriptional elongation by RNAP [12, 37] , are essential for the E 2 -induced gene activation in ER-positive breast cancer cells. While this manuscript was being prepared, a similar study was published [38] that reported BRD4-dependent elongation activity of RNAP in estrogeninduced gene activation. Our data are consistent with the findings of the study [38] , and in addition, we show that BRD2 is also recruited at the promoters of estrogenregulated genes (supplementary Fig. 5 ). These observations underscore the critical role of multiple BET proteins in estrogen regulation of genes in breast cancers and other estrogen target tissues.
JQ1, a small molecule that mimics acetylated lysine, can selectively block the bromodomains of the BET proteins, (BRD2, BRD3, and BRD4) [16] . Expression of each BET protein was confirmed in MCF7 and T47D cells (supplementary Fig. 4) . Using JQ1 as a tool to block BET protein function, we demonstrate complete inhibition of E 2 -induced transcription and growth (Fig. 1) . The stereoisomer of JQ1, ((-) JQ1), which is unable to bind to the bromodomains [16] , failed to inhibit E 2 -induced gene activation as well as growth (Fig. 2) . Thus, recognition of the histone-acetylated lysines by the dual bromodomains of BET proteins is a key event in the E 2 regulation of the genes. Furthermore, our results indicated (supplementary Fig. 3 ) a direct inhibitory role of JQ1 since de novo protein synthesis was not a pre-requisite for the inhibitory effect of JQ1 on the estrogen-regulated genes.
Our results (Fig. 4) on the effect of JQ1 on ER protein expression revealed opposing regulation in MCF7 and T47D cells. Differential E 2 regulation of ER in these cells has been previously reported from our laboratory [23] , where ER mRNA is down-regulated by E 2 in MCF7 cells but up-regulated in T47D cells [23] . In addition, ER protein is known to undergo ubiquitin-mediated degradation by E 2 in MCF7 and other cells [39] [40] [41] . In this study, we provide evidence that BET proteins are involved in maintaining the basal ER mRNA levels in both MCF7 and T47D cells as JQ1 treatment down-regulated the ER mRNA in both the cell lines (Fig. 4c, d ). However, short-term (6 h) combination treatment of E 2 and JQ1 reduced the ER protein levels in MCF7 cells only (Fig. 4a, b) . This outcome was most likely due to the additive effect of reduced mRNA by JQ1 and E 2 -mediated ER protein degradation. While the loss of ER in MCF7 cells was not responsible for the inhibitory effects of JQ1 (Fig. 4e-g and supplementary  Fig. 2) , the contrasting regulation of ER protein in MCF7 and T47D cells in presence of JQ1 ? E2 indicates alternative mechanisms for the maintenance of ER protein levels in diverse breast cancer cells.
Since JQ1 did not disrupt either the E 2 -induced recruitment of ER and SRC3 at the promoters or the histone hyper-acetylation in the region (Fig. 5) , BET protein function is not clearly essential for either the binding of ER at the ERE or formation of the initial transcription complex at the promoters, including the recruitment of RNAP (Fig. 6b, f, j) . In contrast, BET protein function was indispensable for the activation and advancement of the RNAP onto the coding region of the E 2 -regulated genes as JQ1 treatment, which blocked recruitment of BET proteins (supplementary Fig. 5 ), and stalled RNAP at the promoters upstream of the transcription start sites (Fig. 6c, g, k) . This establishes BET proteins as an essential component for integrating the E 2 -ER/co-activator complex with RNAP activation. Phosphorylation of serine-2 at the carboxy terminal domain (CTD) of RNAP by positive transcription elongation factor b (PTEF b ), a heterodimer of CDK9 and cyclin T1, precedes transcription elongation function [42, 43] . BET proteins, particularly BRD4, are known to interact with PTEF b [11, 37] , and positively influence transcription by RNAP. Besides BRD4 other BET protein family members, BRD2 and BRD3, have also been shown to couple histone acetylation with transcription [13] . Interestingly, BRD4 protein has also been suggested to activate RNAP independent of PTEF b [44, 45] . Since JQ1 can bind to all the BET protein family members [16] , more than one member may play an important role in the E 2 -mediated transcriptional elongation by RNAP. The transcription elongation is characterized by CDK9-mediated serine-2 phosphorylation of CTD of RNAP [15, 46, 47] and increased density of RNAP into the coding region of the gene body [34] . Recruitment of CDK9 and subsequent activation of RNAP of the estrogen-regulated genes (including TFF1 and GREB1) [48] in MCF7 cells have been previously reported [48] . The observations that BET proteins can interact with CDK9 [11, 37] , coupled with our data strongly suggest that BET proteins are responsible for engaging CDK9 at the promoters of the E 2 -responsive genes. Recent studies have underscored the importance of BET proteins; their association with CDK9 have also been reported in the context of interferon-stimulated genes [49] . These observations attain clinical significance because we recently showed that constitutive high cMYC transcription mediated by CDK9 is a critical determinant of endocrine therapy resistance breast cancers [50] . Therefore, it is reasonable to speculate that inhibition of BET proteins may prove to be clinically beneficial for endocrine therapy refractory breast cancers. Indeed, JQ1 has been successfully used in pre-clinical studies in vivo [16, 18] including for breast cancers driven by cMYC [51] .
Consistent with the functional role of BET proteins, our results (Fig. 6d, h, l) demonstrate that the traveling ratio of RNAP (a measure of the rate of transition from initiation to elongation) at the promoters of E 2 -induced genes was reversed in the presence of JQ1. The E 2 -induced reduction in the traveling ratio (Fig. 6d, h, l) indicated a high density of RNAP at the coding region, which was consistent with high transcription activity. This effect was completely reversed to the vehicle-treated levels by JQ1 treatment for TFF1 and GREB1 (Fig. 6d, h ), suggesting stalling of the RNAP at the promoter region. For XBP1 (Fig. 6l) , very little change was observed in the traveling ratio in presence of JQ1 ? E 2 versus E 2 alone, despite *40 % decrease in RNAP association in the coding region in the presence of JQ1 ? E 2 . XBP1 gene expression may have an E 2 and BET protein-independent component, as evident from the high RNAP recruitment at the promoter and coding region even in the vehicle-treated cells. Moreover, treatment with JQ1 alone was unable to reverse this RNAP recruitment (Fig. 6j, k) . This emphasizes the possibility that not all E 2 -induced genes may be exclusively regulated in a BET protein-dependent manner and other mechanisms may also play important roles. Nonetheless, JQ1 blocked the E 2 -induced growth of breast cancer cells (Fig. 1a, b) by restricting the cells in the 'G1' phase of the cell cycle (supplementary Fig. 1a, b) , suggesting BET proteins as a potential therapeutic target. The E 2 -liganded ER engages in a cyclic recruitment process of the receptor and other factors including the RNAP enzyme at the responsive promoters [1, 4] . It is important to note that BET protein inhibition had a marginal but consistent reduction in the recruitment of RNAP at the promoter region (Fig. 6b , f, j) which was also reported by another study evaluating interferon-stimulated genes [49] . This effect may be due to disruption of the dynamics of the cyclic events or/and to a failure of re-initiation of transcription by RNAP. Further studies are needed to evaluate the role of BET proteins on the cyclical recruitment of the liganded ER and other factors. Nevertheless, the results indicate that the role of BET proteins is largely restricted to regulating advancement of the RNAP and the transcription elongation process without interfering with the initial recruitment of ER and other necessary factors.
In conclusion, our data revealed BET proteins as a factor integrating the ER transcriptional complex with the RNAP activation of E 2 -regulated genes. This study, along with a recent report [38] , enriches our understanding of hormoneinduced ER-mediated transcriptional regulation and defines BET proteins as a critical regulator of transcriptional activation of E 2 -regulated genes in ER-positive breast cancers. Our study further provides opportunities to explore new therapeutic targets for breast cancers.
